Endothelin-1 and aggregation of human platelets in vitro.
Endothelin-1 (ET-1) is a potent vasoconstrictor peptide produced by endothelial cells. We investigated whether ET-1, like other potent endothelium-derived vasoactive agents, interacts directly with human platelets in vitro. Platelet-rich plasma was obtained from healthy male volunteers and incubated with ET-1 (1 microM) or vehicle (sodium chloride 154 mM) for 10 min at 37 degrees C. Platelet aggregation was measured by the Born method, using light transmittance through the plasma sample as an index of activation. Although a significant increase in light transmittance was observed when plasma was incubated with ET-1 compared with vehicle, (3.8 +/- 0.4% versus 2.7 +/- 0.2%; n = 24; p = 0.038), this effect was small and is unlikely to be of biologic significance. To investigate the possibility that ET-1-stimulated platelet nitric oxide (NO) synthesis might be masking a direct aggregatory effect of ET-1, in a second study in six subjects NG-monomethyl-L-arginine (L-NMMA, 10 and 100 microM), an inhibitor of NO synthase, was preincubated with the plasma before the addition of ET-1 (1 nM and 1 microM). No significant difference was observed whether samples were incubated with L-NMMA alone or with L-NMMA and ET-1. The results of this study suggest that ET-1 does not have a major direct effect as a platelet aggregating agent.